Eosinophil activation

Across TCGA cell cohorts, RNA activity of the Eosinophil activation pathway is significantly associated with the drug response of multiple features, with the BLOOD_Myeloma cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Cisplatin, Gefitinib, and AZD7762, each associated with the pathway in up to 1 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Cisplatin grouped by Eosinophil activation-low versus -high activity in BLOOD_Myeloma.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Myeloma	Cisplatin →	-0.575	-2.258	<.001	.013	1	1
BLOOD_Myeloma	Gefitinib →	-0.570	-2.258	.002	.013	1	1
BLOOD_Myeloma	AZD7762 →	-1.210	-2.258	.019	.013	1	1
BLOOD_Myeloma	Tanespimycin →	-0.989	-2.258	.023	.013	1	1
BLOOD_Myeloma	Motesanib →	-0.555	-2.258	.004	.013	1	1
BLOOD_Myeloma	Doramapimod →	-0.714	-2.258	.029	.013	1	1

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Cisplatin by Eosinophil activation activity — BLOOD_Myeloma

Explore this box plot interactively →